Mind Medicine

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

The,Gap,Hanging,Sign,On,The,Building,At,The,Headquarters

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BURL

COST

LOGI

LUNR

MNMD

RPTX

SSTK

Gap To Rally Over 69%? Here Are 10 Top Analyst Forecasts For Friday

Westlake

Initiation

This Westlake Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Artificial-Intelligence-Photo-by-PopTika copy

Cannabis

Psychedelics

ATAI

CMPS

DELCF

AI and psychedelic medicine are merging, with research showing AI&#39;s role in drug discovery, trials, and personalized mental health care.

AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine Inc

Press Releases

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

MindMed to Be Added to the Nasdaq Biotechnology Index

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

MindMed to Present at Leerink's Global Healthcare Conference 2025

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Comments

Mind Medicine

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga